Consistent with these findings, a number of meta-analyses and in vitro studies have reported that classical non-steroidal anti-inflammatory drugs (NSAIDs) [21] and selective COX-2 inhibitors [22] provided protection against CRC incidence, reduced mortality and improved chemosensitivity and the efficacy of anticancer drugs when co-administrated [23]. This evidence concerns the gene PTGS2 and colorectal carcinoma.